Statistical methods for composite analysis of recurrent and terminal events in clinical trials.

In long-term clinical studies, recurrent event data are frequently collected to contrast the efficacy of two different treatments. However, the recurrent event process can be stopped by a terminal event, such as death. For analyzing recurrent event and terminal event data, joint frailty modeling has recently received considerable attention because it makes it possible to study the joint evolution over time of both recurrent and terminal event processes and gives consistent and efficient parameters. For a two-arm clinical trial design based on these data sets, there has been limited research on investigating the balanced design, let alone adaptive treatment allocation. Although equal sample size allocation obtained for both treatments is intuitively first adopted in a trial design, if one treatment is expected to be superior, it may be desirable to allocate more subjects to the effective treatment. In this article, we calculate the required sample size based on restricted randomization and then propose a target response-adaptive randomization procedure for recurrent and terminal event outcomes based on the joint frailty model. A randomization procedure, the doubly adaptive biased coin design that targets some optimal allocations, is implemented. The proposed adaptive treatment allocation schemes have been shown to be capable of reducing the number of trial participants who receive inferior treatment while simultaneously reaching an optimal target, as well as retaining a comparable test power as compared to a restricted randomization design. Finally, two clinical studies, the COAPT trial and the A-HeFT trial, are used to illustrate the advantages of adopting the proposed procedure.

Introduction: Recurrent event data are common in many longitudinal studies. Often, a terminating event such as death can be correlated with the recurrent event process. A shared frailty model applied to account for the association between recurrent and terminal events. In some situations, a fraction of subjects experience neither recurrent events nor death; these subjects are cured.
 Methods: In this paper, we discussed the Bayesian approach of a joint frailty model for recurrent and terminal events in the presence of cure fraction. We compared estimates of parameters in the Frequentist and Bayesian approaches via simulation studies in various sample sizes; we applied the joint frailty model in the presence of cure fraction with Frequentist and Bayesian approaches for breast cancer.
 Results: In small sample size Bayesian approach compared to Frequentist approach had a smaller standard error and mean square error, and the coverage probabilities close to nominal level of 95%. Also, in Bayesian approach, the sampling means of the estimated standard errors were close to the empirical standard error.
 Conclusion: The simulation results suggested that when sample size was small, the use of Bayesian joint frailty model in the presence of cure fraction led to more efficiency in parameter estimation and statistical inference.

In clinical and observational studies, the event of interest can often recur on the same subject. In a more complicated situation, there exists a terminal event (e.g., death) which stops the recurrent event process. In many such instances, the terminal event is strongly correlated with the recurrent event process. We consider the recurrent/terminal event setting and model the dependence through a shared gamma frailty that is included in both the recurrent event rate and terminal event hazard functions. Conditional on the frailty, a model is specified only for the marginal recurrent event process, hence avoiding the strong Poisson-type assumptions traditionally used. Analysis is based on estimating functions that allow for estimation of covariate effects on the recurrent event rate and terminal event hazard. The method also permits estimation of the degree of association between the two processes. Closed-form asymptotic variance estimators are proposed. The proposed method is evaluated through simulations to assess the applicability of the asymptotic results in finite samples and the sensitivity of the method to its underlying assumptions. The methods can be extended in straightforward ways to accommodate multiple types of recurrent and terminal events. Finally, the methods are illustrated in an analysis of hospitalization data for patients in an international multi-center study of outcomes among dialysis patients.

In clinical and observational studies, recurrent event data (e.g., hospitalization) with a terminal event (e.g., death) are often encountered. In many instances, the terminal event is strongly correlated with the recurrent event process. In this article, we propose a semiparametric method to jointly model the recurrent and terminal event processes. The dependence is modeled by a shared gamma frailty that is included in both the recurrent event rate and terminal event hazard function. Marginal models are used to estimate the regression effects on the terminal and recurrent event processes, and a Poisson model is used to estimate the dispersion of the frailty variable. A sandwich estimator is used to achieve additional robustness. An analysis of hospitalization data for patients in the peritoneal dialysis study is presented to illustrate the proposed method.

Objectives. Using composite endpoints and/or only first events in clinical research result in information loss and alternative statistical methods which incorporate recurrent event data exist. We compared information-loss under traditional analyses to alternative models. Design. We conducted a retrospective analysis of patients who underwent percutaneous coronary intervention (Jan2010-Dec2014) and constructed Cox models for a composite endpoint (readmission/death), a shared frailty model for recurrent events, and a joint frailty (JF) model to simultaneously account for recurrent and terminal events and evaluated the impact of heart failure (HF) on the outcome. Results. Among 4901 patients, 2047(41.8%) experienced a readmission or death within 1 year. Of those with recurrent events, 60% had ≥1 readmission and 6% had >4; a total of 121(2.5%) patients died during follow-up. The presence of HF conferred an adjusted Hazard ratio (HR) of 1.32 (95% CI: 1.18–1.47, p < .001) for the risk of composite endpoint (Cox model), 1.44 (95% CI: 1.36–1.52, p < .001) in the frailty model, and 1.34 (95% CI:1.22–1.46, p < .001) in the JF model. However, HF was not associated with death (HR 0.87, 95% CI: 0.52–1.48, p = .61) in the JF model. Conclusions. Using a composite endpoint and/or only the first event yields substantial loss of information, as many individuals endure >1 event. JF models reduce bias by simultaneously providing event-specific HRs for recurrent and terminal events.

Recurrent events could be stopped by a terminal event, which commonly occurs in biomedical and clinical studies. In this situation, dependent censoring is encountered because of potential dependence between these two event processes, leading to invalid inference if analyzing recurrent events alone. The joint frailty model is one of the widely used approaches to jointly model these two processes by sharing the same frailty term. One important assumption is that recurrent and terminal event processes are conditionally independent given the subject-level frailty; however, this could be violated when the dependency may also depend on time-varying covariates across recurrences. Furthermore, marginal correlation between two event processes based on traditional frailty modeling has no closed form solution for estimation with vague interpretation. In order to fill these gaps, we propose a novel joint frailty-copula approach to model recurrent events and a terminal event with relaxed assumptions. Metropolis-Hastings within the Gibbs Sampler algorithm is used for parameter estimation. Extensive simulation studies are conducted to evaluate the efficiency, robustness, and predictive performance of our proposal. The simulation results show that compared with the joint frailty model, the bias and mean squared error of the proposal is smaller when the conditional independence assumption is violated. Finally, we apply our method into a real example extracted from the MarketScan database to study the association between recurrent strokes and mortality.

Recurrent events like repeated hospitalization, cancer tumour recurrences, and many others occur frequently. The follow-up on recurrent events may be stopped by a terminal event like death. It is obvious that if the frequencies of recurrent events are more, then it may lead to a terminal event and in this case terminal event becomes ‘dependent’. In this article, we study a joint modelling and analysis of recurrent events with a dependent terminal event. Here, the proportional intensity model for the recurrent events process and the proportional hazard model for the terminal event time are taken. To account for the association between recurrent events and terminal events, mixing frailty or random effect is studied rather than available pure frailty. In our case, the distribution of frailty is introduced as a mixture of folded normal distribution and gamma distribution rather than using pure gamma distribution. An estimation procedure in the joint frailty model is applied to estimate the parameters of the model. This method is close to the method of minimum chi-square rather than a complicated one. An extensive simulation study has been performed to estimate the model parameters and the performances are evaluated based on bias and MSE criteria. Further from an application point of view, the method is illustrated to a hospital readmission data for colorectal cancer patients.

Recurrent events are commonly encountered in biomedical studies. In many situations, there exist terminal events, such as death, which are potentially related to the recurrent events. Joint models of recurrent and terminal events have been proposed to address the correlation between recurrent events and terminal events. However, there is a dearth of suitable methods to rigorously investigate the causal mechanisms between specific exposures, recurrent events, and terminal events. For example, it is of interest to know how much of the total effect of the primary exposure of interest on the terminal event is through the recurrent events, and whether preventing recurrent event occurrences could lead to better overall survival. In this work, we propose a formal causal mediation analysis method to compute the natural direct and indirect effects. A novel joint modeling approach is used to take the recurrent event process as the mediator and the survival endpoint as the outcome. This new joint modeling approach allows us to relax the commonly used "sequential ignorability" assumption. Simulation studies show that our new model has good finite sample performance in estimating both model parameters and mediation effects. We apply our method to an AIDS study to evaluate how much of the comparative effectiveness of the two treatments and the effect of CD4 counts on the overall survival are mediated by recurrent opportunistic infections.

Models and methods for the analysis of recurrent event data have seen considerable development over the past 20years. These developments are motivated in part by the diverse and important set of problems in which recurrent events arise in public health, industry, sociology, science, technology and other fields. Intensity-based models represent the most useful way of understanding the dynamics of event processes since they facilitate the characterization of instantaneous risk of events as a function of process history. Random effect models have appeal when interest lies in characterizing variation between individuals in risk of events or addressing dependence within individuals over time in event counts over disjoint intervals, or gap times. In many settings however, such as clinical trials, interest lies in estimating the marginal rate and mean functions and using these as a basis for treatment comparisons. Analysis based onmarginal methods often require stronger assumptions regarding the observation process, however, to ensure they are valid in the presence of censoring and terminal events. This special issue contains a number of fascinating articles on innovative methods for the analysis of recurrent events addressing outstanding statistical and subject-area problems. Schaubel and Zhang (2011) consider the problem of inference regarding treatment effects on a recurrent event process with a terminal event when treatment is not randomized. The authors use inverse probability of treatment weights to adjust for covariate imbalances between treatment groups, and investigate the use of multiple

Recurrent event data are frequently encountered in clinical and observational studies related to biomedical science, econometrics, reliability and demography. In some situations, recurrent events serve as important indicators for evaluating disease progression, health deterioration, or insurance risk. In statistical literature, non informative censoring is typically assumed when statistical methods and theories are developed for analyzing recurrent event data. In many applications, however, there may exist a terminal event, such as death, that stops the follow-up, and it is the correlation of this terminal event with the recurrent event process that is of interest. This work considers joint modeling and analysis of recurrent event and terminal event data, with the focus primarily on determining how the terminal event process and the recurrent event process are correlated (i.e. does the frequency of the recurrent event influence the risk of the terminal event). We propose a joint model of the recurrent event process and the terminal event, linked through a common subject-specific latent variable, in which the proportional intensity model is used for modeling the recurrent event process and the additive hazards model is used for modeling the terminal event time.

Clinical trials are often designed to assess the effect of therapeutic interventions on the incidence of recurrent events in the presence of a dependent terminal event such as death. Statistical methods based on multistate analysis have considerable appeal in this setting since they can incorporate changes in risk with each event occurrence, a dependence between the recurrent event and the terminal event, and event-dependent censoring. To date, however, there has been limited development of statistical methods for the design of trials involving recurrent and terminal events. Based on the asymptotic distribution of regression coefficients from a multiplicative intensity Markov regression model, we derive sample size formulas to address power requirements for both the recurrent and terminal event processes. We consider the design of trials for which separate marginal hypothesis tests are of interest for the recurrent and terminal event processes and deal with both superiority and non-inferiority tests. Simulation studies confirm that the designs satisfy the nominal power requirements in both settings, and an application to a trial evaluating the effect of a bisphosphonate on skeletal complications is given for illustration.

When a recurrent event process is ended by death, this may imply dependent censoring if the two processes are associated. Such dependent censoring would have to be modeled to obtain a valid inference. Moreover, the dependence between the recurrence process and the terminal event may be the primary topic of interest. Joint frailty models for recurrent events and death, which include a separate dependence parameter, have been proposed for exactly observed recurrence times. However, in many situations, only the number of events experienced during consecutive time intervals are available. We propose a method for estimating a joint frailty model based on such interval counts and observed or independently censored terminal events. The baseline rates of the two processes are modeled by piecewise constant functions, and Gaussian quadrature is used to approximate the marginal likelihood. Covariates can be included in a proportional rates setting. The observation intervals for the recurrent event counts can differ between individuals. Furthermore, we adapt a score test for the association between recurrent events and death to the setting in which only individual interval counts are observed. We study the performance of both approaches via simulation studies, and exemplify the methodology in a biodemographic study of the dependence between budding rates and mortality in the species Eleutheria dichotoma.

Composite outcomes are frequently adopted as primary endpoints in clinical trials as they consider fatal and non-fatal consequences of the disease under study and lead to higher event rates. Such analyses of time to first event are suboptimal for a chronic disease such as heart failure, characterised by recurrent hospitalisations, as information on repeats is ignored. We present a comparison of methods of analysing data on repeat hospitalisations, using data from major trials in heart failure. In addition to describing each method and its estimated treatment effect and statistical significance, we investigated statistical power using bootstrapping techniques. Recurrent heart failure hospitalisations were analysed using the Andersen-Gill, Poisson and Negative Binomial methods. Analyses of recurrent events can be confounded by the competing risk of death. Death was incorporated into analyses by treating it as an additional event in the recurrent event process and by considering methods that jointly model heart failure hospitalisations and mortality. We used a parametric joint frailty model to analyse the recurrent heart failure hospitalisations and time to cardiovascular death simultaneously. Our analyses show that methods taking account of repeat hospital admissions demonstrate a larger treatment benefit than the conventional time to first event analysis, even when accounting for death. Inclusion of recurrent events also leads to a considerable gain in statistical power compared to the time to first event approach. It seems plausible that in future heart failure trials, treatment benefit would not be confined to first hospitalisations only and so recurrent events should be routinely incorporated.

Recurrent event data occur in many clinical and observational studies, and in these situations, there may exist a terminal event such as death that is related to the recurrent event of interest. In addition, sometimes more than one type of recurrent events may occur, that is, one may encounter multivariate recurrent event data with some dependent terminal event. For the analysis of such data, one must take into account the dependence among different types of recurrent events and that between the recurrent events and the terminal event. In this paper, we extend a method for univariate recurrent and terminal events and propose a joint modeling approach for regression analysis of the data and establish the finite and asymptotic properties of the resulting estimates of unknown parameters. The method is applied to a set of bivariate recurrent event data arising from a long-term follow-up study of childhood cancer survivors.

Joint analysis of recurrent and nonrecurrent terminal events has attracted substantial attention in literature. However, there lacks formal methodology for such analysis when the event time data are on discrete scales, even though some modeling and inference strategies have been developed for discrete-time survival analysis. We propose a discrete-time joint modeling approach for the analysis of recurrent and terminal events where the two types of events may be correlated with each other. The proposed joint modeling assumes a shared frailty to account for the dependence among recurrent events and between the recurrent and the terminal terminal events. Also, the joint modeling allows for time-dependent covariates and rich families of transformation models for the recurrent and terminal events. A major advantage of our approach is that it does not assume a distribution for the frailty, nor does it assume a Poisson process for the analysis of the recurrent event. The utility of the proposed analysis is illustrated by simulation studies and two real applications, where the application to the biochemists' rank promotion data jointly analyzes the biochemists' citation numbers and times to rank promotion, and the application to the scleroderma lung study data jointly analyzes the adverse events and off-drug time among patients with the symptomatic scleroderma-related interstitial lungdisease.